On Tuesday, Fiserv Inc (NASDAQ:FISV)’s shares declined -0.40% to $85.70.
Fiserv, Inc. (FISV), a leading global provider of financial services technology solutions, declared recently that PBC Credit Union, based in West Palm Beach, Florida, has expanded its long-term relationship with Fiserv, upgrading its DataSafe® account processing platform and adding integrated digital solutions to enhance member services. The credit union added Mobiliti™ for mobile banking, Loancierge® for Credit Unions for automated lending, Wisdom™: Accounting for comprehensive accounting and Wisdom: 5300 Call Report Assistant for call report functionality.
The credit union has also renewed its commitment to the CheckFree® RXP® electronic bill payment solution and credit and debit processing from Fiserv.
Fiserv, Inc., together with its auxiliaries, provides financial services technology worldwide. The company’s Payments and Industry Products segment provides debit, credit, and prepaid card processing and services; electronic bill payment and presentment services; Internet and mobile banking software and services; person-to-person payment services; and other electronic payments software and services.
CyrusOne Inc (NASDAQ:CONE)’s shares dropped -1.54% to $30.08.
CyrusOne Inc. (CONE) has priced a public offering of 11,300,000 shares of its common stock at a price to the public of $30.00 per share. All of the shares of common stock were offered by CyrusOne. The underwriters have been granted an option to purchase up to 1,695,000 additional shares of common stock from CyrusOne at the public offering price, less underwriting discounts. Subject to customary conditions, the offering is predictable to close on or about June 26, 2015.
Citigroup, Goldman, Sachs & Co., Morgan Stanley, KeyBanc Capital Markets, Barclays, J.P. Morgan, Deutsche Bank Securities, RBC Capital Markets, TD Securities and Jefferies acted as joint-bookrunners for the offering. Stifel, SunTrust Robinson Humphrey and Raymond James acted as co-managers for the offering.
CyrusOne Inc., a real estate investment trust (REIT), owns, operates, and develops enterprise-class, carrier-neutral, and multi-tenant data center properties. The company provides mission-critical data center facilities that protect and ensure the continued operation of information technology infrastructure.
At the end of Tuesday’s trade, DURECT Corporation (NASDAQ:DRRX)‘s shares surged 5.96% to $2.49.
DURECT Corporation (DRRX) declared that, based on feedback from the FDA, it plans to conduct a new POSIDUR™ (SABER®-Bupivacaine) Phase 3 clinical trial compriseing of about 300 patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery. DURECT anticipates starting the trial in the fall of 2015 and anticipates that it will take about one year to complete enrollment.
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. It provides ALZET product line comprising osmotic pumps and accessories that are used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers, which are used as raw materials for pharmaceutical and medical device under the LACTEL brand. It also focuses on developing products for various chronic and episodic, or acute medical conditions, counting pain, central nervous system disorders, metabolic disorders, cardiovascular disease, ophthalmic disorders, and other diseases.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), ended its Tuesday’s trading session with 2.01% gain, and closed at $131.62.
Vertex Pharmaceuticals Incorporated (VRTX) declared that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018.
Dr. Bhatia is a physician and engineer and has been a professor at the Massachusetts Institute of Technology (MIT) since 2005. She presently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the MIT Institute for Medical Engineering and Science and Electrical Engineering and Computer Science (EECS). She also presently serves as a Biomedical Engineer in the Department of Medicine for Brigham and Women’s Hospital, an investigator for the Howard Hughes Medical Institute, a member of the Koch Institute for Integrative Cancer Research at MIT and a member of the Broad Institute. She recently received the Heinz Award for Technology, the Economy, and Employment from the Heinz Family Foundation and the Lemelson-MIT Prize for her dedication to STEM education and to improving human health through technological innovations. From 1998 to 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego. Dr. Bhatia holds a B.S. in Biomedical Engineering from Brown University, an M.S. in Mechanical Engineering and Ph.D. in Biomedical Engineering from MIT, and an M.D. from Harvard Medical School.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
